Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sberbank's Supervisory Board recommends dividends based on 2023 results

4/23/24 SBER

M.Video-Eldorado marketplace assortment grew 1.5 times

4/23/24 MVID

Board of Directors of Tatneft recommended that dividends be paid for 2023

4/23/24 TATN

Rosbank may be valued at 0.9-1.1 capital

4/23/24 ROSB

Rosbank may be valued at 0.9-1.1 capital

4/23/24 T

Government will consider measures to support Rusal in the near future

4/23/24 RUAL

Qiwi estimates loss on sale of Russian business at ₽37 billion

4/23/24 QIWI

QIWI reported for 2023 by IFRS

4/23/24 QIWI

Ministry of Energy agreed with the price of modernization of Vladivostok CHPP-2

4/23/24 HYDR

Cian moves to Russia

4/22/24 CIAN